Cm28, a scorpion toxin having a unique primary structure, inhibits KV1.2 and KV1.3 with high affinity

The Cm28 in the venom of Centruroides margaritatus is a short peptide consisting of 27 amino acid residues with a mol wt of 2,820 D. Cm28 has <40% similarity with other known α-KTx from scorpions and lacks the typical functional dyad (lysine-tyrosine) required to block KV channels. However, its unique sequence contains the three disulfide-bond traits of the α-KTx scorpion toxin family. We propose that Cm28 is the first example of a new subfamily of α-KTxs, registered with the systematic number α-KTx32.1. Cm28 inhibited voltage-gated K+ channels KV1.2 and KV1.3 with Kd values of 0.96 and 1.3 nM, respectively. There was no significant shift in the conductance-voltage (G-V) relationship for any of the channels in the presence of toxin. Toxin binding kinetics showed that the association and dissociation rates are consistent with a bimolecular interaction between the peptide and the channel. Based on these, we conclude that Cm28 is not a gating modifier but rather a pore blocker. In a selectivity assay, Cm28 at 150 nM concentration (>100× Kd value for KV1.3) did not inhibit KV1.5, KV11.1, KCa1.1, and KCa3.1 K+ channels; NaV1.5 and NaV1.4 Na+ channels; or the hHV1 H+ channel but blocked ∼27% of the KV1.1 current. In a biological functional assay, Cm28 strongly inhibited the expression of the activation markers interleukin-2 receptor and CD40 ligand in anti-CD3-activated human CD4+ effector memory T lymphocytes. Cm28, due to its unique structure, may serve as a template for the generation of novel peptides targeting KV1.3 in autoimmune diseases.

[1]  G. Tajti,et al.  Optimization of Pichia pastoris Expression System for High-Level Production of Margatoxin , 2021, Frontiers in Pharmacology.

[2]  Oriol Vinyals,et al.  Highly accurate protein structure prediction with AlphaFold , 2021, Nature.

[3]  N. Pastor,et al.  Colombian Scorpion Centruroides margaritatus: Purification and Characterization of a Gamma Potassium Toxin with Full-Block Activity on the hERG1 Channel , 2021, Toxins.

[4]  L. Pardo,et al.  Discovery of KV1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges , 2021, Medicinal research reviews.

[5]  H. Drost,et al.  Sensitive protein alignments at tree-of-life scale using DIAMOND , 2021, Nature Methods.

[6]  O. Dym,et al.  A molecular lid mechanism of K+ channel blocker action revealed by a cone peptide. , 2021, Journal of molecular biology.

[7]  G. Tajti,et al.  The Kv1.3 K+ channel in the immune system and its “precision pharmacology” using peptide toxins , 2021, Biologia Futura.

[8]  Silvio C. E. Tosatto,et al.  The InterPro protein families and domains database: 20 years on , 2020, Nucleic Acids Res..

[9]  Silvio C. E. Tosatto,et al.  Pfam: The protein families database in 2021 , 2020, Nucleic Acids Res..

[10]  S. Gaál,et al.  Shaker-IR K+ channel gating in heavy water: Role of structural water molecules in inactivation , 2016, The Journal of general physiology.

[11]  A. Arcangeli,et al.  Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy , 2021, Frontiers in Pharmacology.

[12]  M. Gómez-Lim,et al.  Cysteine‐Rich Peptides: Hyperstable Scaffolds for Protein Engineering , 2020, Chembiochem : a European journal of chemical biology.

[13]  R. Norton,et al.  The voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides. , 2020, Biochemical pharmacology.

[14]  S. Rangaraju,et al.  Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson's disease. , 2020, The Journal of clinical investigation.

[15]  Yonghua Ji,et al.  Kv1.3 Channel as a Key Therapeutic Target for Neuroinflammatory Diseases: State of the Art and Beyond , 2020, Frontiers in Neuroscience.

[16]  Olga Chernomor,et al.  IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in the Genomic Era , 2019, bioRxiv.

[17]  R. Efremov,et al.  Kalium 2.0, a comprehensive database of polypeptide ligands of potassium channels , 2019, Scientific Data.

[18]  A. Felipe,et al.  Fighting rheumatoid arthritis: Kv1.3 as a therapeutic target. , 2019, Biochemical pharmacology.

[19]  O. Dym,et al.  Pore-modulating toxins exploit inherent slow inactivation to block K+ channels , 2019, Proceedings of the National Academy of Sciences.

[20]  M Mirdita,et al.  MMseqs2 desktop and local web server app for fast, interactive sequence searches , 2018, bioRxiv.

[21]  L. Possani,et al.  Kv1.3 channel blockade with the Vm24 scorpion toxin attenuates the CD4+ effector memory T cell response to TCR stimulation , 2018, Cell Communication and Signaling.

[22]  R. Norton,et al.  Structure, folding and stability of a minimal homologue from Anemonia sulcata of the sea anemone potassium channel blocker ShK , 2018, Peptides.

[23]  E. De Pauw,et al.  APETx4, a Novel Sea Anemone Toxin and a Modulator of the Cancer-Relevant Potassium Channel KV10.1 , 2017, Marine drugs.

[24]  E. Muñoz-Elías,et al.  Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial , 2017, PloS one.

[25]  A. von Haeseler,et al.  UFBoot2: Improving the Ultrafast Bootstrap Approximation , 2017, bioRxiv.

[26]  Thomas K. F. Wong,et al.  ModelFinder: Fast Model Selection for Accurate Phylogenetic Estimates , 2017, Nature Methods.

[27]  D. Rokyta,et al.  Venom‐gland transcriptomics and venom proteomics of the black‐back scorpion (Hadrurus spadix) reveal detectability challenges and an unexplored realm of animal toxin diversity , 2017, Toxicon : official journal of the International Society on Toxinology.

[28]  Vijay S. Pande,et al.  OpenMM 7: Rapid development of high performance algorithms for molecular dynamics , 2016, bioRxiv.

[29]  T. Wise-Draper,et al.  Kv1.3 Channels Mark Functionally Competent CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Cancer. , 2017, Cancer research.

[30]  P. Herdewijn,et al.  Structural and Functional Elucidation of Peptide Ts11 Shows Evidence of a Novel Subfamily of Scorpion Venom Toxins , 2016, Toxins.

[31]  Y. Ji,et al.  Mapping the Interaction Anatomy of BmP02 on Kv1.3 Channel , 2016, Scientific Reports.

[32]  M. Péter,et al.  7DHC-induced changes of Kv1.3 operation contributes to modified T cell function in Smith-Lemli-Opitz syndrome , 2016, Pflügers Archiv - European Journal of Physiology.

[33]  Kai-Chien Yang,et al.  Mechanisms contributing to myocardial potassium channel diversity, regulation and remodeling. , 2016, Trends in cardiovascular medicine.

[34]  K. Kövér,et al.  An engineered scorpion toxin analogue with improved Kv1.3 selectivity displays reduced conformational flexibility , 2015, Scientific Reports.

[35]  S. Feske,et al.  Ion channels in innate and adaptive immunity. , 2015, Annual review of immunology.

[36]  R. Norton,et al.  Development of Highly Selective Kv1.3-Blocking Peptides Based on the Sea Anemone Peptide ShK , 2015, Marine drugs.

[37]  Ernesto Ortiz,et al.  Scorpion venom components as potential candidates for drug development , 2014, Toxicon.

[38]  Z. Varga,et al.  Margatoxin is a non-selective inhibitor of human Kv1.3 K+ channels. , 2014, Toxicon : official journal of the International Society on Toxinology.

[39]  R. Norton,et al.  A potent and Kv1.3-selective analogue of the scorpion toxin HsTX1 as a potential therapeutic for autoimmune diseases , 2014, Scientific Reports.

[40]  Christine Beeton,et al.  Ion channels and anti-cancer immunity , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.

[41]  K. Katoh,et al.  MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability , 2013, Molecular biology and evolution.

[42]  Y. Rosenstein,et al.  Vm24, a Natural Immunosuppressive Peptide, Potently and Selectively Blocks Kv1.3 Potassium Channels of Human T Cells , 2012, Molecular Pharmacology.

[43]  S. Feske,et al.  Ion channels , 2013, Thorax.

[44]  R. C. Rodríguez de la Vega,et al.  Structure, function, and chemical synthesis of Vaejovis mexicanus peptide 24: a novel potent blocker of Kv1.3 potassium channels of human T lymphocytes. , 2012, Biochemistry.

[45]  Shunyi Zhu,et al.  Two dyad-free Shaker-type K⁺ channel blockers from scorpion venom. , 2012, Toxicon : official journal of the International Society on Toxinology.

[46]  S. Oyama,et al.  Looking over toxin-K(+) channel interactions. Clues from the structural and functional characterization of α-KTx toxin Tc32, a Kv1.3 channel blocker. , 2012, Biochemistry.

[47]  H. Wulff,et al.  The lymphocyte potassium channels Kv1.3 and KCa3.1 as targets for immunosuppression , 2011, Drug development research.

[48]  R. Norton,et al.  Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases. , 2011, Inflammation & allergy drug targets.

[49]  B. Vásárhelyi,et al.  Lymphocyte activation in type 1 diabetes mellitus: the increased significance of Kv1.3 potassium channels. , 2010, Immunology letters.

[50]  L. Possani,et al.  Tst26, a novel peptide blocker of Kv1.2 and Kv1.3 channels from the venom of Tityus stigmurus. , 2009, Toxicon : official journal of the International Society on Toxinology.

[51]  K. Chandy,et al.  The functional network of ion channels in T lymphocytes , 2009, Immunological reviews.

[52]  R. C. Rodríguez de la Vega,et al.  A selective blocker of Kv1.2 and Kv1.3 potassium channels from the venom of the scorpion Centruroides suffusus suffusus. , 2008, Biochemical pharmacology.

[53]  S. J. Kehl,et al.  An activation gating switch in Kv1.2 is localized to a threonine residue in the S2-S3 linker. , 2007, Biophysical journal.

[54]  S. Griffey,et al.  Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases , 2006, Proceedings of the National Academy of Sciences.

[55]  R. C. Rodríguez de la Vega,et al.  K+ channel blockers: novel tools to inhibit T cell activation leading to specific immunosuppression. , 2006, Current pharmaceutical design.

[56]  J. Tytgat,et al.  A novel toxin from the venom of the scorpion Tityus trivittatus, is the first member of a new α‐KTX subfamily , 2006, FEBS letters.

[57]  M. De Waard,et al.  Evidence for Domain-specific Recognition of SK and Kv Channels by MTX and HsTx1 Scorpion Toxins* , 2004, Journal of Biological Chemistry.

[58]  R. C. Rodríguez de la Vega,et al.  Current views on scorpion toxins specific for K+-channels. , 2004, Toxicon : official journal of the International Society on Toxinology.

[59]  M. Ayeb,et al.  Kbot1, a three disulfide bridges toxin from Buthus occitanus tunetanus venom highly active on both SK and Kv channels , 2004, Peptides.

[60]  B. Sakmann,et al.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches , 1981, Pflügers Archiv.

[61]  M. Delepierre,et al.  The 'functional' dyad of scorpion toxin Pi1 is not itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels. , 2004, The Biochemical journal.

[62]  P. Calabresi,et al.  The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. , 2003, The Journal of clinical investigation.

[63]  R. C. Rodríguez de la Vega,et al.  Novel interactions between K+ channels and scorpion toxins. , 2003, Trends in pharmacological sciences.

[64]  R. C. Rodríguez de la Vega,et al.  Two novel toxins from the Amazonian scorpion Tityus cambridgei that block Kv1.3 and Shaker B K(+)-channels with distinctly different affinities. , 2002, Biochimica et biophysica acta.

[65]  Shoba Ranganathan,et al.  kappa-Hefutoxin1, a novel toxin from the scorpion Heterometrus fulvipes with unique structure and function. Importance of the functional diad in potassium channel selectivity. , 2002, The Journal of biological chemistry.

[66]  E. Horjales,et al.  Effects of Toxins Pi2 and Pi3 on Human T Lymphocyte Kv1.3 Channels: The Role of Glu7 and Lys24 , 2001, The Journal of Membrane Biology.

[67]  P. Libby,et al.  CD154 (CD40 ligand). , 2000, The international journal of biochemistry & cell biology.

[68]  G A Gutman,et al.  A unified nomenclature for short-chain peptides isolated from scorpion venoms: alpha-KTx molecular subfamilies. , 1999, Trends in pharmacological sciences.

[69]  B. Rudy,et al.  Molecular Diversity of K+ Channels , 1999, Annals of the New York Academy of Sciences.

[70]  E. Serfling,et al.  The Interleukin 2 Receptor α Chain/CD25 Promoter Is a Target for Nuclear Factor of Activated T Cells , 1998, The Journal of experimental medicine.

[71]  O. Pongs,et al.  A four-disulphide-bridged toxin, with high affinity towards voltage-gated K+ channels, isolated from Heterometrus spinnifer (Scorpionidae) venom. , 1997, The Biochemical journal.

[72]  R. MacKinnon,et al.  Mapping the Receptor Site for Hanatoxin, a Gating Modifier of Voltage-Dependent K+ Channels , 1997, Neuron.

[73]  C. Roumestand,et al.  On the Convergent Evolution of Animal Toxins , 1997, The Journal of Biological Chemistry.

[74]  James E. Hall,et al.  Topology of the pore-region of a K+ channel revealed by the NMR-derived structures of scorpion toxins , 1995, Neuron.

[75]  C. Miller,et al.  Mechanism of charybdotoxin block of a voltage-gated K+ channel. , 1993, Biophysical journal.

[76]  M. Garcia-Calvo,et al.  Purification, characterization, and biosynthesis of margatoxin, a component of Centruroides margaritatus venom that selectively inhibits voltage-dependent potassium channels. , 1993, The Journal of biological chemistry.